Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients.

Autor: Nsiangani Lusambo N; Eye Department, Teaching Hospital, Medical School, University of Kinshasa, Kinshasa, Democratic Republic of Congo. lnsiangani@yahoo.fr., Kaimbo Wa Kaimbo D; Eye Department, Teaching Hospital, Medical School, University of Kinshasa, Kinshasa, Democratic Republic of Congo., Ngoyi Mumba DM; Parasitology Department, Teaching Hospital, Medical school, University of Kinshasa, Kinshasa, Democratic Republic of Congo., de-la-Torre A; Neuroscience Research Group (NEUROS), Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Jazyk: angličtina
Zdroj: BMC ophthalmology [BMC Ophthalmol] 2023 Oct 31; Vol. 23 (1), pp. 440. Date of Electronic Publication: 2023 Oct 31.
DOI: 10.1186/s12886-023-03183-x
Abstrakt: Background: Ocular toxoplasmosis (OT) is the leading cause of infectious posterior uveitis in several areas worldwide. The combination of Trimethoprim/Sulfamethoxazole (TMP/SMX) has been presented as an attractive alternative to the "classic' treatment therapy (Pyrimethamine/Sulfadiazine).
Methods: A prospective study was carried out between February 2020 and September 2021 in 2 ophthalmic centers in Kinshasa. This study aimed to describe TMP/SMX treatment outcomes for OT in a cohort of immunocompetent Congolese patients.
Results: 54 patients were included, with a mean age at presentation of 37.5 ± 13.6 years old and a Male-Female ratio of 1.45:1. Three patients (5.6%) presented a recurrence during the follow-up period. At the end of the follow-up, improvement in VA and resolution of inflammation concerned 75.9% and 77.5% of patients, respectively. Cataracts (3.7%), macular scars (3.7%), and vitreous opacities (3.7%) were the principal causes of non-improvement in VA. Treatment-related adverse events were present in 10 patients (18.5%); gastrointestinal (14.8%) and dermatological (3.7%) adverse events were the most frequent. Dermatological adverse events led to discontinuation of treatment.
Conclusion: TMP/SMX regimen appears to be a safe and effective treatment for OT in Congolese patients. The low cost and the accessibility of the molecules make this regimen an option for treating OT in resource-limited countries.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: